Media stories about ZIOPHARM Oncology (NASDAQ:ZIOP) have trended positive on Friday, AlphaOne reports. The research firm, a unit of Accern, identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ZIOPHARM Oncology earned a news sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted AlphaOne Sentiment Analysis’s analysis:
- Stock Performance Check on Shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) – Jonesboro Recorder (jonesbororecorder.com)
- ETFs with exposure to ZIOPHARM Oncology, Inc. : June 15, 2017 (finance.yahoo.com)
- Technical Indicators Summary:ZIOPHARM Oncology, Inc. (ZIOP) has a value of $5.47 per share While HCA Healthcare … – Stocks Gallery (stocksgallery.com)
- ZIOPHARM Oncology (ZIOP) Presents At Jefferies 2017 Global Healthcare Conference – Slideshow (seekingalpha.com)
- The Q2 2017 EPS Estimates for ZIOPHARM Oncology Inc. Cut by Analyst (ZIOP) – BangaloreWeekly (bangaloreweekly.com)
Shares of ZIOPHARM Oncology (ZIOP) traded down 1.29% during trading on Friday, hitting $5.37. The stock had a trading volume of 1,824,200 shares. ZIOPHARM Oncology has a 52 week low of $4.45 and a 52 week high of $7.88. The stock’s market capitalization is $701.86 million. The stock’s 50 day moving average is $6.51 and its 200 day moving average is $6.37.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, May 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. ZIOPHARM Oncology had a negative return on equity of 364.49% and a negative net margin of 2,600.79%. The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.71 million. The firm’s revenue for the quarter was down 18.8% on a year-over-year basis. On average, equities research analysts expect that ZIOPHARM Oncology will post ($0.58) earnings per share for the current fiscal year.
ZIOP has been the topic of several analyst reports. Zacks Investment Research cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, April 6th. HC Wainwright initiated coverage on ZIOPHARM Oncology in a research report on Thursday, June 1st. They issued a “buy” rating and a $9.50 target price on the stock. Finally, Griffin Securities restated a “buy” rating and issued a $23.00 target price on shares of ZIOPHARM Oncology in a research report on Tuesday, February 28th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $11.00.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.